QUOTE AND NEWS
Market Intelligence Center  Jul 15  Comment 
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Becton, Dickinson and Co (BDX). Look at the Sep. '14 $120.00 covered call for a net debit in the $116.63 area. This trade has a...
Market Intelligence Center  Jun 24  Comment 
After Monday’s trading in Becton, Dickinson and Co (BDX) the option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center uncovered a trade that offers a 3.59% return, or 14.90% annualized (for...
Market Intelligence Center  Jun 11  Comment 
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Becton, Dickinson and Co (BDX) that should provide a 2.92% return in just 101 days. Sell one Sep. '14 call at the $120.00 level for each 100...
SeekingAlpha  May 29  Comment 
By Dividends4Life: Becton, Dickinson and Co. (BDX). Below are some highlights from the above linked analysis: Company Description: Becton, Dickinson and Co. provides a wide range of medical devices and diagnostic products used in hospitals,...
SeekingAlpha  May 22  Comment 
By Sure Dividend: Medtronic (MDT) and Becton, Dickinson and Company (BDX) are both global manufacturers and distributors of medical, diagnostic, bioscience and therapy products. Both companies are dividend aristocrats with a long history of...
SeekingAlpha  May 19  Comment 
By Sure Dividend: Becton, Dickinson and Company (BDX) is a global producer of medical, diagnostic, and bioscience products. BDX was founded in 1897, and has paid increasing dividends for 42 consecutive years. The business has continued to evolve...
SeekingAlpha  May 1  Comment 
Becton, Dickinson and Company (BDX) F2Q 2014 Earnings Conference Call May 1, 2014 8:00 a.m. ET Executives Monique Dolecki - VP of Investor Relations Chris Reidy - CFO Bill Kozy - COO Tom Polen - Group President Linda Tharby -...
TheStreet.com  May 1  Comment 
NEW YORK (TheStreet) -- Becton Dickinson & Company released its second quarter 2014 earnings results before the opening bell on Monday, falling short of analysts revenue estimates but beating earnings guidance.The medical technology company...
newratings.com  May 1  Comment 
WASHINGTON (dpa-AFX) - Medical technology company Becton, Dickinson and Co. (BDX) said second-quarter net income increased to $287 million from $276 million in the previous year. Earnings per hare advanced to $1.45 from $1.39. On average, 18...
Wall Street Journal  May 1  Comment 
Becton Dickinson & Co. said its fiscal second-quarter profit rose 4% as revenue grew across the company's segments, but overall results underperformed analysts' expectations.




 
TOP CONTRIBUTORS


Becton, Dickinson and Company(NYSE:BDX) is a leading hospital supply company with 2007 revenues of $6,360 million. BDX generates revenues through three business divisions: Medical (54%), Diagnostics (30%) and Biosciences (16%). [1] Through its Medical divison, BDX is the world's largest manufacturer and distributor of products such as needles and syringes. In fact, BDX built the first factory in the U.S. specifically for producing needles, syringes, and thermometers. [2]The disagnostic division deals with safely collecting and analyzing various specimens to detect diseases and the Biosciences division sells research and clinical tools which are used in the study of cells. [3]

Although BDX built its business manufacturing basic instruments such as needles and scalpels, the company has grown in recent years by introducting safety engineered products. [4] For example, the company introduced the auto-disable injection device, which is a syringe that locks in automatically once used and cannot be reused. BDX's technological improvements also make their products safer for the staff that uses them. For example, BDX's safety-guarded sharps prevent needlestick injuries for doctors and nurses, and are now mandatory in most of the hospitals across the U.S. [5] One further benefit is that safety engineered products also carry higher margins than traditional products. [6]

Business Overview

BD has three main operating segments: BD Medical, BD Diagnostics and BD Biosciences.

  • BD Medical: is the largest and most profitable division of the company. It produces a broad array of medical devices such as needles, syringes, surgical blades & scalpels, IV catheters, and syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The primary markets served by BD Medical are hospitals, clinics, physician offices, and retail pharmacies.[7]
  • BD Diagnostics: provides systems used to collect medical samples and diagnostic systems for testing the samples. This includes products such as safety-engineered blood collection systems, cervical cancer screening systems, and others. The primary markets served by BD Diagnostics include hospitals, laboratories, blood banks, and physician offices. [8]
  • BD Biosciences: produces research and clinical tools for the study of cells, which is used to treat patients, develop new drugs, vaccines, etc. Products include devices which sort and analyze cells, cell imaging systems, and other products. The primary markets served by BD Biosciences include research and clinical laboratories, biotechnology and pharmaceutical companies, and hospitals.[9]

BD got its start through syringes and other basic products, and to this day, BD Medical division remains the core of the company, contributing 54% of revenue in 2007. Diagnostics (30%) and Biosciences (16%) constituted the remaining 46% of revenues. [10]

BDX 2007 Annual Report
BDX 2007 Annual Report[11]

In 2007, BDX had revenue of $6,360 million, an increase of 11% from the prior year.[12] Medical revenues increased 10% to $3.4 billion, Biosciences revenues increased 13% to $1.0 billion, and Diagnostics revenue increased 11% to $1.9 billion.[13]

BDX 2007 Annual Report
BDX 2007 Annual Report[14]

International revenues accounted for 52% of the company's business, with Europe being the largest international market. US sales accounted for the remaining 48% of business. Both international and US sales grew by 11% in 2007. [15]

BDX 2007 Annual Report
BDX 2007 Annual Report[16]

Key Trends and Forces

Medicare coverage patterns

Health coverage is an important determining factor when patients and doctors choose among various treatment options and medical products. Medicare coverage is particularly significant in that it directly affects over forty million Americans, how much patients have to pay for BDX products (primarily BD Medical products), and how much BDX will receive in payments from Medicare. Currently, Medicare and other third party payors are emphasizing more cost-effective products, by limiting the reimbursement they will cover. Furthermore, even if a new BDX product is cleared by the FDA, BDX faces limited demand until Medicare and other payors approve it for reimbursement. Both of these factors can affect BDX's sales.

Government Regulation

BDX and its competitors are all heavily affected by government regulation, especially by the FDA, which is responsible for regulating food, dietary supplements, drugs, medical devices, and other products in the United States. Without FDA approval, BDX cannot sell any of its medical products to the public. If any of BDX's devices fail FDA approval, it can adversely affect the company's sales.

Diabetes

Diabetes currently affects around 200 million people worldwide, including 21 million people in the U.S. It is estimated that more than $132 billion is spent annually on diabetes and its complications. BDX currently has several products such as syringes and pen needles for the injection of insulin, which is essential for the treatment of diabetes. In 2007, Diabetes Care products generated nearly $700 M in revenue for the firm. These and future diabetes related products represent an opportunity for BDX to generate additional revenue in this large and expanding market.

Competition

BDX faces tough competition in all of its business divisions. It competes with Covidien in the Medical division, Gen-Probe (GPRO) in Diagnostics division, and Beckman Coulter (BEC) in its Biosciences division.

BDX and Top Competitors (2007)
Company Total Sales Net Income
BDX $6,359 M [17] $890 M [18]
Covidien $10,170 M [19] ($342 M) [20]
Gen-Probe (GPRO) $325 M [21] $59 M [22]
Beckman Coulter (BEC) $2,528 M [23] $187 M [24]



References

  1. BDX 2007 10k, Ex 13
  2. Company Website
  3. BDX 2007 10k, Item 1
  4. BDX 2007 10k, Item 1
  5. Needlestick.org
  6. BDX 2007 10k, Ex 13, Pg 21
  7. BDX 2007 10k, Pg 1
  8. BDX 2007 10k, Pg 1
  9. BDX 2007 10k, Pg 1
  10. BDX 2007 10k, Ex 13
  11. BDX 2007 10k, Ex 13
  12. BDX 2007 10k, Ex 13, Pg 20
  13. BDX 2007 10k, Ex 13, Pgs 21-22
  14. BDX 2007 10k, Ex 13
  15. BDX 2007 10k, Ex 13
  16. BDX 2007 10k, II-3
  17. BDX 2007 10k, Ex 13
  18. BDX 2007 10k, Ex 13
  19. COV 2007 10k
  20. COV 2007 10k
  21. GPRO 2006 10k
  22. GPRO 2006 10k
  23. BEC 2006 10k
  24. BEC 2006 10k
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki